on activated carbon to depro-
tect the remaining two benzyl
groups and generate the free C-
nucleoside 14. Compound 14
was too polar to be purified by
normal silica gel chromatogra-
phy. Therefore, without any fur-
ther purification, three in situ
reactions were subsequently
performed on 14: 1) protection
of the two OH groups by TMS-
Cl in pyridine; 2) reaction with
Fmoc-Cl to protect the two
NH2 groups; 3) deprotection of
the TMS groups to liberate 3’-
OH and 5’-OH to give 15 (63%
for four steps from 13 to 15).
The 5’-OH group was then se-
lectively protected by reaction
with 4’,4’-dimethoxytrityl chlo-
ride in pyridine to give 16
(78%), which was finally con-
verted to target monomer 17 by
reaction with 2-cyanoethyl-N,N-
diisopropylaminochlorophos-
phine under an argon atmos-
phere (82%). The overall yield
of the desired AE-MAP phos-
phoramidite monomer from
compound 1 was 4.5%.
TFO synthesis and UV triplex
melting studies: Standard solid-
phase phosphoramidite meth-
ods were used to synthesize the
Scheme 1. i) Methyl bromoacetate, NaH, DMF, À58C, 5 h, 97%; ii) LiBH4, THF, RT, 1 h, 72%; iii) phthal-
imide, PPh3, DEAD, THF, RT, 1 h, 99%; iv) H2NNH2·H2O, EtOH, RT, 24 h, 92%; v) BnBr, NaH, DMF, 08C,
5 h, 89%; vi) 80% acetic acid, 1% conc. sulfuric acid, 808C, 6 h, 96%; vii) 4-methylmorpholine-N-oxide, tetra-
propylammonium perruthenate, molecular sieves, CH2Cl2, RT, 5 h, 85%; viii) 912, nBuLi, THF, À788C, 8 h,
48%; ix) triethylsilane, BF3·Et2O, CH2Cl2, À788C, 26 h, 57%; x) CF3COOH, RT, 5 h, 85%; xi) BCl3, CH2Cl2,
À788C, 7 h, 88%; xii) Pd/C, MeOH, 508C, 18 h, n.a.; xiii) chlorotrimethylsilane, pyridine, RT, 2 h; Fmoc-Cl (in
anhydrous MeCN), RT, 4 h; KF (in water), RT, 20 min; 63% for four steps from 13 to 15; xiv) DMTrCl, 8 h,
RT, 78%; xv) 2-cyanoethyl-N, -diisopropylchlorophosphine, DIPEA, CH2Cl2, 2 h, RT, 82%.
oligonucleotides
containing
AE-MAP. The Fmoc-protecting
group not only permits AE-
MAP to be incorporated into
oligonucleotides using standard
cycles including capping with
Treatment of 6 with 80% acetic acid and a catalytic amount
of concentrated sulfuric acid gave 7, which was oxidized to
the corresponding ribolactone 8 (85%) using tetrapropylam-
monium perruthenate and 4-methylmorpholine-N-oxide.
The subsequent three steps are identical to those for Me-
MAP and MOE-MAP:[12] The resultant ribolactone was
coupled with dibenzylated 2-amino-5-bromo-3-methyl-pyri-
dine (9)[12] in the presence of nBuLi in THF to produce
hemiacetal 10 as a mixture of a and b anomers, which was
subsequently reduced with Et3SiH/BF3·Et2O in CH2Cl2 to
give the b-anomer of C-nucleoside 11 (57%). The p-me-
thoxybenzyl group was then cleaved in trifluoroacetic acid
to provide 12 (85%). Removal of the four benzyl groups on
12 was performed in two steps; 3’- and 5’-positions were de-
protected in BF3/CH2Cl2 at À788C to afford dibenzyl pro-
tected 13 (88%), followed by hydrogenation with palladium
acetic anhydride, but also allows oligonucleotide deprotec-
tion under mild conditions.[12] Pure oligonucleotides can be
obtained more readily when Fmoc is chosen to protect the
2-amino group of aminopyridine than when trifluoroacetyl
protection is used. This is because in the latter case the cap-
ping step with acetic anhydride has to be omitted to prevent
unwanted acetylation of N2 of the aminopyridine (HPLC
and CE chromatograms in the Supporting Information).
The triplex-stabilizing properties of AE-MAP were com-
pared with Me-MAP, MOE-MAP, dMAP, 5-methyl-2’-de-
oxycytidine
(
MeC),
2’-O-aminoethyl-5-methylcytidine
(AE-MeC) and dC (Figure 1).[12] The TFOs also contain 2’-
aminoethoxy-T (t in Figure 1D), an analogue of thymidine
that is used in vivo to confer thermodynamic and enzymatic
stability on TFOs.[14,15] The 2’-methoxyethyl analogue of S12
(S in Figure 1D) stabilizes CG inversions and improves sta-
14852
ꢀ 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Chem. Eur. J. 2011, 17, 14851 – 14856